JPMorgan Chase & Co. Raises Position in Kodiak Sciences Inc. (NASDAQ:KOD)

JPMorgan Chase & Co. boosted its stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 194.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 131,646 shares of the company's stock after purchasing an additional 86,998 shares during the period. JPMorgan Chase & Co. owned about 0.25% of Kodiak Sciences worth $1,310,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. State Street Corp lifted its position in shares of Kodiak Sciences by 1.8% during the 3rd quarter. State Street Corp now owns 816,634 shares of the company's stock valued at $2,131,000 after buying an additional 14,711 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Kodiak Sciences by 1.7% in the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company's stock worth $2,007,000 after purchasing an additional 12,783 shares during the period. Peapod Lane Capital LLC purchased a new stake in shares of Kodiak Sciences in the fourth quarter worth $1,660,000. Bank of New York Mellon Corp increased its stake in shares of Kodiak Sciences by 5.3% in the fourth quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company's stock worth $976,000 after purchasing an additional 4,927 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Kodiak Sciences by 65.5% during the 3rd quarter. Barclays PLC now owns 79,658 shares of the company's stock valued at $208,000 after purchasing an additional 31,527 shares during the period. Institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "neutral" rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research report on Monday, March 31st.

Kodiak Sciences Trading Down 0.3 %

Shares of NASDAQ:KOD traded down $0.02 during midday trading on Thursday, reaching $4.35. 31,415 shares of the company were exchanged, compared to its average volume of 341,784. The stock has a market cap of $229.21 million, a PE ratio of -1.19 and a beta of 2.40. The business's fifty day moving average is $3.24 and its two-hundred day moving average is $5.43. Kodiak Sciences Inc. has a one year low of $1.92 and a one year high of $11.60.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.06. As a group, sell-side analysts expect that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.